Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay.
"We are excited to announce the start of ARIES clinical trials as planned, which represents a key milestone in our commercial launch schedule," said Homi Shamir, President and CEO of Luminex.
Shamir continued, "Because we designed ARIES to be an easy to use solution that solves many of the problems and challenges laboratories face each day, we are highly optimistic in the market potential for this innovative platform. We continue to advance along our projected launch schedule, and expect to initiate clinical trials for additional ARIES assays in the coming months. With ARIES, we are solidifying a platform which we expect will accelerate growth for years to come."
The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.